Lilly's oral weight-loss pill shows promise amid pharma shakeup: TIME
Listen to article
In a detailed feature by TIME Magazine, pharmaceutical giant Eli Lilly has unveiled promising early results from clinical trials of its experimental oral drug orforglipron, a GLP-1-based treatment for diabetes and weight loss. The development marks a potentially transformative moment for both the company and the obesity-treatment landscape.
The data, presented during a critical meeting at Lilly's Indianapolis headquarters on April 15, showed that orforglipron lowered blood sugar levels and aided weight loss without serious side effects like liver toxicity—an issue that recently led Pfizer to abandon its own oral drug in the same category. Orforglipron's results were comparable to Lilly's injectable blockbuster tirzepatide (Mounjaro).
If approved by the FDA, orforglipron could become the first oral GLP-1 drug for weight loss on the market. Unlike competing drugs, it requires no dietary restrictions or timing constraints and is easier and cheaper to manufacture and distribute—especially in areas where injectables are impractical.
Lilly's CEO David Ricks and Chief Scientific Officer Dr Dan Skovronsky credited the company's agile approach, culture shift, and high-speed innovation for the drug's progress. The pill was licensed from Japan's Chugai in 2018 and developed 30–40% faster than industry averages, according to Ricks.
The company is investing heavily in domestic production, anticipating a surge in demand. Trials are ongoing to evaluate orforglipron's effectiveness in non-diabetic obesity and other conditions like hypertension. If successful, the drug could dramatically expand access to obesity treatments and redefine the market.
This effort is part of Lilly's broader push to break industry norms, including direct-to-consumer models like Lilly Direct, which bypass intermediaries to lower costs. With additional breakthroughs like the Alzheimer's drug Kisunla, Lilly is now the world's most valuable pharma firm—and possibly the first on track to a $1 trillion valuation.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Express Tribune
5 days ago
- Express Tribune
Weight-loss drugs like Ozempic, Wegovy, and Mounjaro may lower oral contraceptive effectiveness., UK's MHRA warns
Listen to article The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has issued an alert urging women using weight-loss medications such as Ozempic, Wegovy, and Mounjaro to use effective contraception after receiving multiple reports of pregnancies among users, The Guardian reported on June 5, 2025. The alert follows 40 reports of pregnancy in women taking these weight-loss drugs, prompting the MHRA to warn that Mounjaro, in particular, may reduce the effectiveness of oral contraceptives. The agency advises that women taking this drug use barrier contraception, such as condoms, in addition to oral contraceptives, according to The Guardian. The MHRA received 26 pregnancy-related reports concerning Mounjaro and an additional eight reports linked to semaglutide-based drugs (Ozempic and Wegovy). Another weight-loss medication, Saxenda, which contains liraglutide, also garnered nine reports. Read more: Ozempic shows promise in reversing liver disease, research finds While it's unclear whether the pregnancies were unintended, some women confirmed their pregnancies were unplanned, as reported by The Guardian. The MHRA has emphasised that these medications should not be used during pregnancy or while trying to conceive due to insufficient safety data regarding potential harm to a developing baby. Women taking these drugs are also advised to continue contraception for up to two months after stopping the medication before attempting to become pregnant, as noted by the health agency. Also read: Popular weight loss drug Ozempic linked to higher risk of blindness Dr. Channa Jayasena, a consultant in reproductive endocrinology, noted that GLP-1 medications like Ozempic and Wegovy are effective in aiding weight loss but could increase fertility in women with obesity by enhancing fertility. However, these drugs may also interfere with the absorption of oral contraceptives, potentially increasing the risk of unintended pregnancies. This was also highlighted in The Guardian's coverage. Read: Ozempic-fueled weight loss takes over Oscars 2025 as Hollywood's size zero trend returns Dr. Alison Cave, the MHRA's chief safety officer, urged patients not to misuse these medications for weight loss, stressing that they are licensed for specific medical conditions and not for cosmetic purposes. She further recommended that patients read the provided patient information leaflets and consult healthcare professionals before using these powerful treatments, as reported in The Guardian.
Business Recorder
29-04-2025
- Business Recorder
Merck to invest $1 billion in new Delaware plant to boost US manufacturing
US drugmaker Merck said on Tuesday it is investing $1 billion in a new Delaware plant to expand domestic production as it prepares to deal with President Donald Trump's tariffs. The new facility will produce biologic drugs and Keytruda, becoming Merck's first in-house U.S. site to make the blockbuster cancer treatment, the company said. Merck said last week its biggest tariff exposure is through Keytruda and it has enough U.S. inventory for this year. It estimated $200 million in additional costs for the levies implemented to date. The company expects labs at the new facility to be fully operational by 2028 and produce experimental drugs by 2030. The new plant would create at least 500 full-time jobs and about 4,000 construction vacancies, the company said. Merck opened a $1 billion facility at its North Carolina site last month to boost U.S. production. The Trump administration has been putting pressure on U.S. drugmakers to move their medicine production to the country and announced probes into drug imports that set the stage for levies in the sector. U.S. drugmakers, including Eli Lilly and Johnson & Johnson, have recently announced additional investments to boost domestic production amid the tariff threat.
Express Tribune
29-04-2025
- Express Tribune
Mike Wood, LeapFrog founder, dies by physician-assisted suicide due to Alzheimer's diagnosis
Mike Wood, founder of the educational toy company LeapFrog Enterprises, has died by physician-assisted suicide following a diagnosis of Alzheimer's disease. He was 72. Wood passed away earlier this month in Switzerland, where physician-assisted suicide is legal, his brother confirmed. He was reportedly "surrounded by family" at the time of his death. According to family statements, Wood chose to end his life before the Alzheimer's disease progressed significantly, maintaining his desire for dignity and control in the face of a devastating illness. Wood, a California resident, launched LeapFrog in the mid-1990s after noticing his three-year-old son's struggles with reading. The company quickly rose to prominence with the 1999 release of the LeapPad, a groundbreaking educational device that became the best-selling toy during the 2000 holiday season. Wood stepped away from the company in 2004 but remained a respected figure in the educational technology space. LeapFrog Enterprises paid tribute to its founder in a statement posted on Instagram. "We are saddened by the loss of LeapFrog founder, Mike Wood," the company said. "His passion to find a new way to help his child learn led to something remarkable... We loved working with Mike and are honoured to continue what he started." Wood is survived by his son and three grandchildren. His death marks the passing of a visionary entrepreneur whose innovations in early childhood education technology have impacted millions of children worldwide.
